Episode 77 Part 2

Cold Calling Your Way Into Venture Capital

Philip Borden (2/4)

“What I could offer is I'm willing to work hard. I'm willing to learn. I'm willing to be a good contributor.”

Cold Calling Your Way Into Venture Capital | Philip Borden (2/4)

Show notes

“What I could offer is I'm willing to work hard. I'm willing to learn. I'm willing to be a good contributor.”

Philip Borden explains how realizing he did not want to pursue a PhD or spend his career at the lab bench led him toward venture capital. With a molecular biology degree, limited finance experience, and a list of biotech VC firms, he picked up the phone and cold-called his way into Frazier Healthcare in Seattle.

Philip shares why personal relationships, phone calls, and in-person conversations matter more than email when building trust. He discusses selling as communication and listening, the humility required to ask for an opportunity, and the culture lessons he learned from working alongside experienced investors.

He also explains why investors owe founders timely, respectful answers, including a clear no. The conversation closes with the small customer rituals Labshares uses to honor entrepreneurs, from ribbon cuttings to creating a fun place to work.

Explore the conversation

Continue with the resources, organizations, and people discussed in this episode.

Sources & resources

Primary links are included when they were available in the episode notes.

Labshares About Us: https://www.labshares.com/about-us Harvard Business School: https://www.hbs.edu/ Duke University: https://www.duke.edu/ University of Washington: https://www.washington.edu/ Amazon: https://www.amazon.com/

Companies & people

Headshot of Philip Borden

About Philip Borden

Philip Borden is the CEO of Labshares, a Greater Boston company that gives emerging biotech teams flexible, capital-efficient access to fully-equipped shared lab space — so scientists can focus on their science instead of managing medical waste, freezer alarms, and five-year leases.

Before Labshares, Philip spent more than two decades as a healthcare investor — from Frazier Healthcare Partners in Seattle, to more than a decade as a general partner at Riverside Partners, and later Galen Partners and Longfellow Healthcare Partners. He's a Duke molecular biologist and a Baker Scholar out of Harvard Business School, and his throughline is a conviction that the biggest edge in biotech isn't the flashiest round — it's staying alive. This is a conversation about relationships, capital efficiency, and the unglamorous discipline that actually keeps companies breathing.

Transcript

Read the complete conversation or jump to a timestamp.